2. Search Result
Search Result
Results for "

Dual

" in MedChemExpress (MCE) Product Catalog:

1222

Inhibitors & Agonists

1

Screening Libraries

5

Fluorescent Dye

4

Biochemical Assay Reagents

32

Peptides

3

MCE Kits

11

Inhibitory Antibodies

43

Natural
Products

21

Recombinant Proteins

25

Isotope-Labeled Compounds

12

Antibodies

13

Click Chemistry

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12299
    WH-4-023
    4 Publications Verification

    Dual LCK/SRC inhibitor

    		 Src Cancer
    WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.
    WH-4-023
  • HY-145708
    Dual AChE-MAO B-IN-2

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    Dual AChE-MAO B-IN-2 is a potent AChE and MAO B dual inhibitor with IC50s of 0.12 µM and 0.01 µM for b>AChE and MAO B, respectively. Dual AChE-MAO B-IN-2 has the potential for the research of Alzheimer’s disease .
    Dual AChE-MAO B-IN-2
  • HY-142955
    Dual photoCORM 1

    		Others Cancer
    Dual photoCORM 1 (compound 5) is metal-free, photochemically active dual CORM. Dual photoCORM 1 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach in cancerous B16F10 cells .
    Dual photoCORM 1
  • HY-144738
    Dual FAAH/sEH-IN-1

    		Epoxide Hydrolase FAAH Inflammation/Immunology
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .
    Dual FAAH/sEH-IN-1
  • HY-151885
    Dual AChE-MAO B-IN-3

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    Dual AChE-MAO B-IN-3 (compound C10) is a potent dual AChE/MAO-B inhibitior, with IC50 values of 0.58 and 0.41 μM, respectively. Dual AChE-MAO B-IN-3 is a dual-binding inhibitor bound to both the catalytic anionic site and peripheral anionic site of AChE. Dual AChE-MAO B-IN-3 can be used for Alzheimer’s disease (AD) research .
    Dual AChE-MAO B-IN-3
  • HY-158695
    Dual AChE-MAO B-IN-4

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    Dual AChE-MAO B-IN-4 (compound 7) is a dual AChE/MAO-B inhibitor, with IC50 values ​​of 261 nM and 15 nM, respectively. Dual AChE-MAO B-IN-4 protects against oxidative damage induced by H2O2 and 6-OHDA in SH-SY5Y cells. Dual AChE-MAO B-IN-4 can penetrate the central nervous system in a cell model that mimics the blood-brain barrier. Dual AChE-MAO B-IN-4 can be used in the study of neurological diseases such as Alzheimer's disease (AD) .
    Dual AChE-MAO B-IN-4
  • HY-145695
    Dual AChE-MAO B-IN-1

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    Dual AChE-MAO B-IN-1 (compound 15) is an orally bioavailable CNS-permeant potent inhibitor of both human AChE (IC50=550 nM) and MAO B (IC50=8.2 nM). Dual AChE-MAO B-IN-1 behaves as a safe and metabolically stable neuroprotective agent, devoid of cytochrome liability .
    Dual AChE-MAO B-IN-1
  • HY-110378
    ISOX-DUAL

    		Epigenetic Reader Domain Others
    ISOX-DUAL is a dual CBP/BRD4 inhibitor with IC50 values of 0.65 μM and 1.5 μM for CBP and BRD4, respectively .
    ISOX-DUAL
  • HY-129426
    PDK1/Akt/Flt dual pathway inhibitor

    		Akt Cancer
    PDK1/Akt/Flt dual pathway inhibitor is one of a component of KP372-1 (HY-15673 ), and inhibits PDK1/Akt/Flt dual pathway .
    PDK1/Akt/Flt dual pathway inhibitor
  • HY-153476
    GIP/GLP-1 dual receptor agonist-1

    		GCGR Metabolic Disease
    GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .
    GIP/GLP-1 dual receptor agonist-1
  • HY-124891
    1-Phenylpyrrole

    N-Phenylpyrrole

    		 Others Others
    1-Phenylpyrrole (N-Phenylpyrrole) has dual fluorescent properties. 1-Phenylpyrrole displays a single band in nonpolar solvents and a second red-shifted fluorescent band in polar solvents .
    1-Phenylpyrrole
  • HY-135140A
    Methyltetrazine-amine hydrochloride

    		Others Others
    Methyltetrazine-Amine, a tetrazine compound, is used for the site-specific dual functionalization of the resulting bioconjugates .
    Methyltetrazine-amine hydrochloride
  • HY-10158S
    Bosutinib-d8

    SKI-606-d8

    		 Isotope-Labeled Compounds Src Bcr-Abl Autophagy Cancer
    Bosutinib-d8 is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively[1][2].
    Bosutinib-d8
  • HY-124891S
    1-Phenylpyrrole-d9

    N-Phenylpyrrole-d9

    		 Isotope-Labeled Compounds Others
    1-Phenylpyrrole-d9 (N-Phenylpyrrole-d9) is the deuterium labeled 1-Phenylpyrrole (HY-124891). 1-Phenylpyrrole (N-Phenylpyrrole) has dual fluorescent properties. 1-Phenylpyrrole displays a single band in nonpolar solvents and a second red-shifted fluorescent band in polar solvents .
    1-Phenylpyrrole-d9
  • HY-19373
    RWJ-445167

    3DP-10017

    		 Thrombin Factor Xa Cardiovascular Disease
    RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
    RWJ-445167
  • HY-163787
    YY173

    		CDK Cancer
    YY173 is a dual inhibitor for CDK4 and CDK6 with IC50 of 7.7 and 88 nM. YY173 inhibits the proliferation of cell Jurkat with an IC50 of 1.46 μM. YY173 can be used for synthesis of PROTAC CDK4/6 degrader 1 (HY-163786) .
    YY173
  • HY-109108A
    Valemetostat tosylate
    1 Publications Verification

    DS-3201 tosylate

    		 Histone Methyltransferase Cancer
    Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma .
    Valemetostat tosylate
  • HY-163786
    PROTAC CDK4/6 degrader 1

    		PROTACs CDK Apoptosis Cancer
    PROTAC CDK4/6 degrader 1 (Compound 7f) is a dual degrader for CDK4 and CDK6 with DC50 of 10.5 and 2.5 nM. PROTAC CDK4/6 degrader 1 inhibits the proliferation of cell Jurkat (IC50 is 0.18 μM), arrests the cell cycle at G1 phase and induces apoptosis. (Pink: ligand for target protein YY173 (HY-163787); Black: linker (HY-163788); Blue: ligand for E3 ligase (HY-10984))
    PROTAC CDK4/6 degrader 1
  • HY-145244
    APN/AKT-IN-1

    		Akt Cancer
    APN/AKT-IN-1 is a potent and dual inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. APN/AKT-IN-1 can effectively inhibit the phosphorylation of GSK3β, the intracellular substrate of AKT .
    APN/AKT-IN-1
  • HY-121087
    BCI-215
    2 Publications Verification

    		 Phosphatase Cancer
    BCI-215 is a potent and tumor cell-selective dual specificity MAPK phosphatase (DUSP-MKP) inhibitor. BCI-215 has cytotoxicity for tumor cells but not normal cells .
    BCI-215
  • HY-101776
    Desmethyl-VS-5584

    Desmethyl-SB2343

    		 mTOR PI3K Cancer
    Desmethyl-VS-5584 is a dimethyl analog of VS-5584 which is an potent and selective mTOR/PI3K dual inhibitor with pyrido [2,3-d] pyrimidine structure .
    Desmethyl-VS-5584
  • HY-155195
    FLT3/CHK1-IN-1

    		Others Cancer
    FLT3/CHK-IN-1 (Compound 18) is a dual inhibitor of FLT3/CHK1. FLT3/CHK-IN-1 is more than 1700 times more selective to c-KI T and greatly reduces hERG affinity with an IC50 value of 58.4 μM. FLT3/CHK-IN-1 inhibits tumor growth in mouse xenotransplantation models inoculated with MV-4-11 cells .
    FLT3/CHK1-IN-1
  • HY-158763
    MPI8

    TG0205221

    		 SARS-CoV Cathepsin Virus Protease Infection
    MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). This dual inhibition enhanced the overall antiviral potency and effect of MPI8. MPI8 can be used in clinical studies of COVID-19 .
    MPI8
  • HY-145723
    MAX-40279

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279
  • HY-145723A
    MAX-40279 hydrochloride

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 hydrochloride is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279 hydrochloride
  • HY-145723B
    MAX-40279 hemifumarate

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279 hemifumarate
  • HY-145723C
    MAX-40279 hemiadipate

    		FLT3 FGFR Inflammation/Immunology Cancer
    MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
    MAX-40279 hemiadipate
  • HY-144824
    Monoamine oxidase/Aromatase-IN-1

    		Cytochrome P450 Monoamine Oxidase Neurological Disease Cancer
    Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and aromatase dual inhibitor with IC50s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer .
    Monoamine oxidase/Aromatase-IN-1
  • HY-146675
    COX/5-LOX-IN-1

    		COX Inflammation/Immunology
    COX/5-LOX-IN-1 (compound 6b) is a potent and dual inhibitor of COX/5-LOX with IC50s of 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. COX/5-LOX-IN-1 has the potential for the research of inflammation diseases .
    COX/5-LOX-IN-1
  • HY-120882
    BM-1197

    UBX1967

    		 Bcl-2 Family Cancer
    BM-1197 (UBX1967) is a potent and selective inhibitor of dual Bcl-2/Bcl-xL, with IC50s of 3.5 nM and 5.2 nM for Bcl-2 and Bcl-xL, respectively. BM-1197 exhibits antitumor effects both in vitro and in vivo .
    BM-1197
  • HY-158264
    SNRI-IN-1

    		Serotonin Transporter Endocrinology
    SNRI-IN-1 (Compound 7a) is a dual serotonin and noradrenaline monoamine reuptake inhibitor, P-glycoprotein Efflux Ratio is 20 .
    SNRI-IN-1
  • HY-18307
    SYN1143

    		c-Met/HGFR Cancer
    SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC50s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK with IC50s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated .
    SYN1143
  • HY-162603
    HDAC-IN-74

    		HDAC DNA/RNA Synthesis Cancer
    HDAC-IN-74 (PA) is a dual HDAC/Rribonucleotide reductase(RR) inhibitor, with IC50 values ​​of 10.80 μM and 9.34 μM for HDAC and HDAC, respectively. HDAC-IN-74 can be used in anticancer research .
    HDAC-IN-74
  • HY-12652
    AZD3147

    		mTOR Cancer
    AZD3147 is a potent, orally active, selective dual inhibitor of mTORC1 and mTORC2 with an IC50 value of 1.5 nM. AZD3147 also has a selective effect on PI3K .
    AZD3147
  • HY-145935
    NT219

    		Insulin Receptor STAT Cancer
    NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases .
    NT219
  • HY-15999A
    Cerdulatinib hydrochloride
    5 Publications Verification

    PRT062070 hydrochloride; PRT2070 hydrochloride

    		 Syk JAK Cancer
    Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies .
    Cerdulatinib hydrochloride
  • HY-131971
    AChE/BChE-IN-1

    		Cholinesterase (ChE) Neurological Disease
    AChE/BChE-IN-1 is a potent and brain-penetrant dual inhibitor of Acetylcholinesterase and Butyrylcholinesterase, with IC50s of 1.06 and 7.3 nM for hAChE and hBChE, respectively. AChE/BChE-IN-1 also has antioxidant activity. AChE/BChE-IN-1 can be used for the research of Alzheimer’s disease .
    AChE/BChE-IN-1
  • HY-147922
    hCAI/II-IN-2

    		Carbonic Anhydrase Inflammation/Immunology
    hCAI/II-IN-2 (compound 2b) is a potent dual hCA I/II inhibitor with Ki values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .
    hCAI/II-IN-2
  • HY-147923
    hCAI/II-IN-3

    		Carbonic Anhydrase Inflammation/Immunology
    hCAI/II-IN-3 (compound 5b) is a potent dual hCA I/II inhibitor with Ki values of 51.25, 13.15 and 42.18 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-3 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .
    hCAI/II-IN-3
  • HY-151211
    BTK-IN-16

    		Btk Inflammation/Immunology Cancer
    BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC50s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia .
    BTK-IN-16
  • HY-12947
    GNE-3511
    5+ Cited Publications

    		 MAP3K Neurological Disease
    GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a Ki of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseases .
    GNE-3511
  • HY-109593
    BMS-813160
    1 Publications Verification

    		 CCR Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC50s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation .
    BMS-813160
  • HY-155160
    COX-2/15-LOX-IN-3

    		Lipoxygenase COX Inflammation/Immunology
    COX-2/15-LOX-IN-3 (compound 5k) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-3 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS, and NO), with specific anti-inflammatory activity .
    COX-2/15-LOX-IN-3
  • HY-155161
    COX-2/15-LOX-IN-4

    		Lipoxygenase COX Inflammation/Immunology
    COX-2/15-LOX-IN-4 (compound 5i) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-4 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS) with specific anti-inflammatory activity .
    COX-2/15-LOX-IN-4
  • HY-158319
    Mutant IDH1/NAMPT-IN-1

    		Apoptosis Isocitrate Dehydrogenase (IDH) NAMPT Cancer
    Mutant IDH1/NAMPT-IN-1 (Compound 23h) is a dual inhibitor of mutant isocitrate dehydrogenase 1 (mutant IDH1) (IC50=14.93 nM) and nicotinamide phosphoribosyltransferase (NAMPT) (IC50=12.56 nM). Mutant IDH1/NAMPT-IN-1 can induce apoptosis. Mutant IDH1/NAMPT-IN-1 crosses the blood-brain barrier effectively .
    Mutant IDH1/NAMPT-IN-1
  • HY-117822
    BRD0209

    		GSK-3 Neurological Disease
    BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC50 = 19 nM; GSK3β IC50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (Ki = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases .
    BRD0209
  • HY-119374
    BRM/BRG1 ATP Inhibitor-1
    15+ Cited Publications

    		 Epigenetic Reader Domain Cancer
    BRM/BRG1 ATP Inhibitor-1 (compound 14) is an orally active allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM. BRM/BRG1 ATP Inhibitor-1 has anticancer activity .
    BRM/BRG1 ATP Inhibitor-1
  • HY-168049
    ZLY06

    		PPAR Akt Metabolic Disease
    ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
    ZLY06
  • HY-168088
    DNMT1/HDAC-IN-1

    		HDAC DNA Methyltransferase Cancer
    DNMT1/HDAC-IN-1 (compound (R)-23a) is a DNMT1/HDAC dual inhibitor (HDAC1:IC50=0.05 μM), HDAC1 is a major HDAC isoform that interacts with DNMT1 in multiple protein complexes for transcriptional silencing of TSGs. DNMT1/HDAC-IN-1 can reshape the tumor immune microenvironment and induce tumor regression, and effectively reverse cancer-specific epigenetic abnormalities .
    DNMT1/HDAC-IN-1
  • HY-115904
    FLT3/CDK4-IN-1

    		CDK FLT3 Cancer
    FLT3/CDK4-IN-1 is a potent, high selective and orally active FLT3/CDK4 dual inhibitor (IC50=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo .
    FLT3/CDK4-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: